Clinical trials: Non-malignant Pain
Opioid-induced Constipation
Long Term Safety of Naldemedine
The purpose of this study is to evaluate the long-term safety of naldemedine for the treatment of constipation due to opioid therapy.
- Trial name
- NCT01965652
- Testing
- Naldemedine
- Where
- 186 sites in United States, Australia and 14 more
- Volunteers
- 1,246 people
- Sponsor
- Shionogi
Chronic Nonmalignant and Nonneuropathic Pain
Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.
The primary objective of this study is to characterize the long-term safety of Hydrocodone Bitartrate (HYD) tablets 20 to 120 mg once-daily in subjects with chronic nonmalignant and nonneuropathic pain.
- Trial name
- NCT01400139
- Testing
- Hydrocodone bitartrate q24h film-coated tablets
- Where
- 98 sites in United States
- Volunteers
- 922 people
- Sponsor
- Purdue Pharma LP
Chronic Pain
An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Thai Participants With Chronic Non-Malignant Pain
The purpose of this study is to evaluate the efficacy and safety of Transdermal Therapeutic System (TTS)-fentanyl patch (transdermal patch containing a drug that is put on the skin so the drug will enter the body through the…
- Trial name
- NCT01816243
- Testing
- TTS-Fentanyl, Morphine
- Where
- 2 sites in Thailand
- Volunteers
- 39 people
- Sponsor
- Janssen-Cilag Ltd.,Thailand
Pain, Osteoarthritis
An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain
The purpose of the study is to assess the long-term safety profile of Tapentadol (CG5503) extended release (ER) at dosages ranging from 100 to 250 mg twice a day in treating patients with moderate to severe chronic pain over a…
- Conditions
- Pain, Osteoarthritis, Low Back Pain
- Trial name
- NCT00487435
- Testing
- Tapentadol (CG5503) Extended Release (ER)
- Where
- 148 sites in United States, Australia and 2 more
- Volunteers
- 1,166 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Chronic Pain
OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant Patients
This is an open-label, randomized, single-dose, parallel group study. The objectives of this study are to assess pharmacokinetics of oxycodone and naloxone from oxycodone/naloxone (OXN) prolonged release (PR) tablet 5/2.5 mg (OXN…
- Trial name
- NCT02880475
- Testing
- OXN PR tablet
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Pain
A Study of the Effectiveness and Safety of Sustained-release Hydromorphone (a Strong Opioid) in Patients With Chronic Noncancer Pain.
The purpose of this study is to compare the effectiveness and safety of sustained- release hydromorphone, formulated to release slowly over time, taken once daily, and controlled- release oxycodone taken twice daily, in patients…
- Trial name
- NCT00261495
- Testing
- OROS hydromorphone HCl, Oxycodone
- Where
- 52 sites in Czechia, Denmark and 8 more
- Volunteers
- 504 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Chronic Pain
An Interventional Study to Compare the Efficacy and Tolerability With Targin® in Non-malignant Chronic Pain (GLORY)
Objectives: 1. Objective of main interest To assess the drop-out rate caused by adverse event* after 6 weeks treatment 2. Further objectives To assess the drop-out rate caused by adverse event* after 1 week treatment To assess…
- Trial name
- NCT01811186
- Testing
- Oxycodone/naloxone
- Where
- South Korea
- Volunteers
- 261 people
- Sponsor
- Mundipharma Korea Ltd
Chronic Nonmalignant Pain
Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study
The objective of this study was to evaluate the long-term safety and tolerability of 7-day BTDS in a 28-week open-label extension phase in subjects with chronic nonmalignant pain syndromes whose pain had been previously…
- Trial name
- NCT01151098
- Testing
- Buprenorphine transdermal patch
- Where
- 19 sites in United States
- Volunteers
- 189 people
- Sponsor
- Purdue Pharma LP